Delivering widespread BRCA testing and PARP inhibition to patients with ovarian cancer
A George, S Kaye, S Banerjee - Nature reviews Clinical oncology, 2017 - nature.com
The treatment of patients with ovarian cancer is rapidly changing following the success of
poly [ADP-ribose] polymerase (PARP) inhibitors in clinical trials. Olaparib is the first PARP …
poly [ADP-ribose] polymerase (PARP) inhibitors in clinical trials. Olaparib is the first PARP …
JM McCuaig, SR Armel, M Care, A Volenik, RH Kim… - Cancers, 2018 - mdpi.com
The combination of increased referral for genetic testing and the current shortage of genetic
counselors has necessitated the development and implementation of alternative models of …
counselors has necessitated the development and implementation of alternative models of …
A cost-effectiveness analysis of multigene testing for all patients with breast cancer
Importance Moving to multigene testing for all women with breast cancer (BC) could identify
many more mutation carriers who can benefit from precision prevention. However, the cost …
many more mutation carriers who can benefit from precision prevention. However, the cost …
Implementation of multigene germline and parallel somatic genetic testing in epithelial ovarian cancer: SIGNPOST study
Simple Summary Multigene testing in ovarian cancer has received increased support due to
its 'applicability for cancer treatment and the impact it has on cancer prevention in families …
its 'applicability for cancer treatment and the impact it has on cancer prevention in families …
Cellular mechanism of gene mutations and potential therapeutic targets in ovarian cancer
T Guo, X Dong, S **e, L Zhang, P Zeng… - Cancer management …, 2021 - Taylor & Francis
Ovarian cancer is a common and complex malignancy with poor prognostic outcome. Most
women with ovarian cancer are diagnosed with advanced stage disease due to a lack of …
women with ovarian cancer are diagnosed with advanced stage disease due to a lack of …
Oncologist-led BRCA 'mainstreaming' in the ovarian cancer clinic: A study of 255 patients and its impact on their management
Although guidelines recommend BRCA testing for all women with non-mucinous epithelial
ovarian cancer, there is significant variability in access to testing across the UK. A germline …
ovarian cancer, there is significant variability in access to testing across the UK. A germline …
Multigene panel germline testing of 1333 Czech patients with ovarian cancer
K Lhotova, L Stolarova, P Zemankova, M Vocka… - Cancers, 2020 - mdpi.com
Ovarian cancer (OC) is the deadliest gynecologic malignancy with a substantial proportion
of hereditary cases and a frequent association with breast cancer (BC). Genetic testing …
of hereditary cases and a frequent association with breast cancer (BC). Genetic testing …
Mainstreamed genetic testing for women with ovarian cancer: first-year experience
Background Ovarian cancer is the fifth most common cause of cancer death for women in
the UK. Up to 18% of cases can be attributed to germline mutations in BRCA1 and BRCA2 …
the UK. Up to 18% of cases can be attributed to germline mutations in BRCA1 and BRCA2 …
Positive experiences of healthcare professionals with a mainstreaming approach of germline genetic testing for women with ovarian cancer
K Bokkers, RP Zweemer, MJ Koudijs, S Stehouwer… - Familial cancer, 2022 - Springer
According to current guidelines, all women with epithelial ovarian cancer are eligible for
genetic testing for BRCA germline pathogenic variants. Unfortunately, not all affected …
genetic testing for BRCA germline pathogenic variants. Unfortunately, not all affected …
Pathology update to the Manchester Scoring System based on testing in over 4000 families
DG Evans, EF Harkness, I Plaskocinska… - Journal of medical …, 2017 - jmg.bmj.com
Background While the requirement for thresholds for testing for mutations in BRCA1/2 is
being questioned, they are likely to remain for individuals unaffected by a relevant cancer. It …
being questioned, they are likely to remain for individuals unaffected by a relevant cancer. It …